Aurobindo Pharma receives final approval for Perindopril Erbumine Tablets 12th November 2009 Aurobindo Pharma Limited is pleased to announce that it's tentatively approved ANDA for Perindopril Erbumine Tablets 2mg, 4mg and 8mg (ANDA No. 079070) has received the final approval from the US Food & Drug Administration (USFDA). Perindopril Erbumine Tablets are the generic equivalent of Solvay Pharmaceuticals' Aceon® Tablets and falls under the CVS segment and indicated for the treatment of patients with essential hypertension. The product will be launched shortly. Aurobindo has a total of 109 ANDA approvals (81 Final approvals and 28 Tentative approvals) from USFDA About Aurobindo Pharma Limited: Aurobindo Pharma Limited (www.aurobindo.com), headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. The company's robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterological, and Anti-Allergics, supported by an outstanding R&D set-up. The Company is marketing these products globally, in over 100 countries. For further information, please contact: Investor Relations Aurobindo Pharma Limited Reg Off: Plot No. 2, Maitrivihar, Ameerpet, Hyderabad Phone: 040-66725000 / 66725401 Email: ir@aurobindo.com Close